DERM 5.74 Stock Price Journey Medical Corporation
Range: | 2.85-8.11 | Vol Avg: | 90300 | Last Div: | 0 | Changes: | 0.17 |
Beta: | 0.92 | Cap: | 0.11B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Fri Nov 12 2021 | Empoloyees: | 41 |
CUSIP: | 48115J109 | CIK: | 0001867066 | ISIN: | US48115J1097 | Country: | US |
CEO: | Mr. Claude Maraoui | Website: | https://journeymedicalcorp.com |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.